StockpollyBeta
Get App
Popularity #1,205
VTRS · NASDAQ · Drug Manufacturers - Specialty & Generic

Viatris (VTRS)

Markets established brands, complex generics, and newer innovative medicines worldwide.

$17.15
After hours−0.03 (−0.17%)
At close$17.18(+0.47%)

In millions of USD, except per-share figures

In millionsQ3 FY23Sep 2023Q4 FY23Dec 2023Q1 FY24Mar 2024Q2 FY24Jun 2024Q3 FY24Sep 2024Q4 FY24Dec 2024Q1 FY25Mar 2025Q2 FY25Jun 2025Q3 FY25Sep 2025Q4 FY25Dec 2025Q1 FY26Mar 2026Q2 FY26Jun 2026
Revenue3,9423,8373,6633,7973,7513,5283,2543,5823,7603,7043,5173,757
Cost of revenue2,2512,2412,1592,3512,2922,3132,0932,2492,3752,5692,3602,300
Gross profit1,6911,5971,5041,4451,4591,2151,1611,3331,3851,1351,1571,457
1,2402,0511,3001,6851,2331,3954,0431,1001,1331,4001,2371,450
Research & development211203200204198207222219250275249248
1,0541,6061,0181,0371,0031,0479489298831,0319291,135
General & administrative000000000001,135
Other expenses−2524283444321422,873−480956067
Operating income452−455204−240226−180−2,882233252−266−806
−50−4011−152−135−347−215−450−260−78−168−70
Interest expense142141138146146120116117120120120121
Other non-operating income−92260−1396−1022799334140−42−48−50
Income before tax402−855205−39291−527−3,097−217−8−343−247−64
Income tax expense71−8991−65−4−10−55−213120−3−42455
Net income from continuing operations332−766114−32695−517−3,042−5−128−340176−119
Net income332−766114−32695−517−3,042−5−128−340176−119
EPS, basic$0.28−$0.64$0.10−$0.27$0.08−$0.43−$2.55−$0.00−$0.11−$0.30$0.15−$0.10
EPS, diluted$0.27−$0.64$0.09−$0.27$0.08−$0.43−$2.55−$0.00−$0.11−$0.30$0.15−$0.10
Weighted average shares, basic1,2001,2001,1951,1911,1941,1931,1921,1731,1651,1531,1551,163
Weighted average shares, diluted1,2081,2001,2101,1911,2001,1931,1921,1731,1651,1531,1751,163
EBITDA1,223−701,034540906340−2,317578800543644653
Depreciation & amortization679644691786670746665678689767676597
EBIT544−714343−246236−406−2,982−101112−223−3257